data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Aligos Therapeutics

(NASDAQ:ALGS)

Intraday

$0.83

0.012[1.47%]

After-Hours

$0.83

0[0.00%]

Perks Buy Compare Brokers

$0.83

0.012[1.47%]

At close: Apr 26

$0.83

0[0.00%]

PreMarket: 7:52AM EDT

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for Aligos Therapeutics Stock (NASDAQ:ALGS)

Aligos Therapeutics Stock (NASDAQ: ALGS)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, April 25, 2024

Aligos Therapeutics Presents Clinical Data At ESCMID 2024 From The ALG-097558 Phase 1 Study
Benzinga Newsdesk - 15 hours ago

Wednesday, April 03, 2024

Aligos Therapeutics Announces First Subjects Dosed In Phase 2a HERALD Study Of ALG-055009 In MASH Subjects
Benzinga Newsdesk - Apr 3, 2024, 8:18AM

Monday, April 01, 2024

Earlier Announced, Aligos Therapeutics Has Been Awarded A $1.3M NIH Contract To Conduct Clinical Development Of A Compound For The Treatment Of Covid-19
Benzinga Newsdesk - Apr 1, 2024, 11:31AM

Wednesday, March 27, 2024

Aligos Therapeutics Presents Clinical Data At APASL 2024 From ALG-055009 And ALG-000184 Phase 1 Studies
Happy Mohamed - Mar 27, 2024, 8:06AM

Monday, March 18, 2024

Aligos Therapeutics Announces Initiation Of Phase 2a HERALD Study Of ALG-055009 In MASH Subjects
Benzinga Newsdesk - Mar 18, 2024, 8:01AM

Friday, March 15, 2024

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Mar 15, 2024, 5:33PM

Tuesday, March 12, 2024

Recap: Aligos Therapeutics Q4 Earnings
Benzinga Insights - Mar 12, 2024, 4:30PM
Aligos Therapeutics Q4 2023 GAAP EPS $(0.22) Beats $(0.27) Estimate, Sales $2.009M Beat $1.600M Estimate
Benzinga Newsdesk - Mar 12, 2024, 4:26PM
Earnings Scheduled For March 12, 2024
Benzinga Insights - Mar 12, 2024, 5:35AM

Monday, March 11, 2024

Aligos Therapeutics Earnings Preview
Benzinga Insights - Mar 11, 2024, 2:00PM

Tuesday, February 20, 2024

Aligos Therapeutics To Host KOL Event To Discuss Phase 2a HERALD Study Of ALG-055009 In MASH On March 7, 2024
Benzinga Newsdesk - Feb 20, 2024, 8:30AM

Friday, December 08, 2023

Why Hello Group Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Avi Kapoor - Dec 8, 2023, 8:05AM

Thursday, December 07, 2023

Aligos Therapeutics shares are trading higher after the company announced it presented clinical data at Hep-DART 2023 from its Phase 1 studies in HBV and NASH.
Benzinga Newsdesk - Dec 7, 2023, 4:32PM
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Dec 7, 2023, 4:31PM
Aligos Therapeutics Presents Clinical Data At Hep-DART 2023 From Phase 1 Studies In HBV And NASH
Benzinga Newsdesk - Dec 7, 2023, 4:18PM

Monday, November 20, 2023

Why Applied UV Shares Are Trading Higher By Around 96%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Nov 20, 2023, 8:19AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Nov 20, 2023, 8:06AM

Friday, November 17, 2023

Aligos Therapeutics Inc Files Prospectus Related To Resale From Time To Time Of Up To 168.7M Shares Of Common Stock, By Selling Securityholders
Benzinga Newsdesk - Nov 17, 2023, 4:42PM

Monday, November 13, 2023

Aligos Therapeutics Presents Clinical And Nonclinical Data At The AASLD Liver Meeting2023 Demonstrating That ALG-055009 Has A Favorable Risk-Benefit Profile
Benzinga Newsdesk - Nov 13, 2023, 8:05AM

Friday, November 10, 2023

Aligos Therapeutics Presents Data At The AASLD Liver Meeting 2023 Demonstrating That Treatment With ALG-000184 Results In Significant Multi-Log Reductions In Hepatitis B Antigens
Benzinga Newsdesk - Nov 10, 2023, 8:10AM

Tuesday, November 07, 2023

Aligos Therapeutics To Present Multiple Posters At AASLD's The Liver Meeting 2023, Highlighting Progress For Its Clinical Stage Portfolio, including Lead THR-β Agonist For The Treatment Of NASH, ALG-055009; ALG-000184, The Company's Lead CAM-E Molecule
Benzinga Newsdesk - Nov 7, 2023, 8:08AM

Friday, November 03, 2023

Aligos Therapeutics To Host KOL Event To Discuss ALG-000184 Phase 1, AASLD Late Breaker Data
Benzinga Newsdesk - Nov 3, 2023, 4:32PM

Thursday, November 02, 2023

Aligos Therapeutics Q3 EPS $(0.41) Beats $(0.47) Estimate, Sales $2.15M Miss $2.50M Estimate
Benzinga Newsdesk - Nov 2, 2023, 4:42PM
Earnings Scheduled For November 2, 2023
Benzinga Insights - Nov 2, 2023, 4:56AM

Wednesday, November 01, 2023

Earnings Outlook For Aligos Therapeutics
Benzinga Insights - Nov 1, 2023, 4:01PM

Friday, October 27, 2023

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Oct 27, 2023, 5:31PM

Monday, October 23, 2023

Why Aligos Therapeutics (ALGS) Stock Is Nosediving
Henry Khederian - Oct 23, 2023, 1:44PM
Aligos Therapeutics shares are trading lower after the company announced $92 million in private placement financing.
Benzinga Newsdesk - Oct 23, 2023, 11:20AM
Aligos Therapeutics Announces $92M Private Placement Financing
Happy Mohamed - Oct 23, 2023, 8:09AM

Wednesday, October 18, 2023

On October 16, 2023, Aligos Therapeutics Entered Into Settlement Agreement With Janssen Biotech Providing For Resolution Of Previously Disclosed Action Brought By Janssen Alleging Breach Of Contract Aligos CEO, Others
Charles Gross - Oct 18, 2023, 8:53AM

Tuesday, October 03, 2023

Aligos Therapeutics Has Been Awarded An $8.5M National Institute Of Allergy And Infectious Diseases Contract To Conduct Nonclinical, Clinical Studies To Advance Its Pan-coronavirus Protease Inhibitor ALG-097558 Into Future Phase 2/3 Studies
Benzinga Newsdesk - Oct 3, 2023, 7:34AM

Thursday, September 21, 2023

Aligos Therapeutics Announces IND Clearance For NASH Lead, ALG-055009
Benzinga Newsdesk - Sep 21, 2023, 7:32AM

Wednesday, September 13, 2023

Chief Medical Officer at Aligos Therapeutics Acquires Company Stock Options Worth 48,000 Shares
Benzinga Insights - Sep 13, 2023, 11:02AM
Chief Executive Officer at Aligos Therapeutics Acquires Company Stock Options Worth 150,000 Shares
Benzinga Insights - Sep 13, 2023, 11:02AM

Thursday, September 07, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Sep 7, 2023, 1:55PM

Thursday, August 03, 2023

Aligos Therapeutics Q2 EPS $(0.43) Beats $(0.49) Estimate, Sales $2.59M Down From $3.69M YoY
Benzinga Newsdesk - Aug 3, 2023, 5:08PM
Earnings Scheduled For August 3, 2023
Benzinga Insights - Aug 3, 2023, 6:59AM

Wednesday, June 21, 2023

Aligos Therapeutics Presents Data From Its Liver Disease Programs At The European Association For The Study Of The Liver Congress 2023
Benzinga Newsdesk - Jun 21, 2023, 4:33PM

Wednesday, June 07, 2023

Aligos Therapeutics To Present Data On Its Liver Disease Programs At The European Association For The Study Of the Liver (EASL) Congress 2023 Jun. 21-24
Benzinga Newsdesk - Jun 7, 2023, 7:31AM

Monday, May 15, 2023

Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - May 15, 2023, 1:45PM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - May 15, 2023, 9:06AM
Aligos Therapeutics shares are trading higher after the company announced a research collaboration and development agreement with Xiamen Amoytop Biotech Co. for the use of Aligos' oligonucleotide platform for the treatment of liver diseases.
Benzinga Newsdesk - May 15, 2023, 8:39AM
Why NeoGames Shares Are Trading Higher By 121%; Here Are 20 Stocks Moving Premarket
Lisa Levin - May 15, 2023, 8:03AM
Aligos Therapeutics Announced Friday A Research Collaboration And Development Agreement With Xiamen Amoytop Biotech Co. Ltd. For Use Of Aligos' Oligonucleotide Platform For Treatment Of Liver Diseases
Charles Gross - May 15, 2023, 6:07AM

Thursday, May 04, 2023

Recap: Aligos Therapeutics Q1 Earnings
Benzinga Insights - May 4, 2023, 5:45PM
Aligos Therapeutics Q1 EPS $(0.53) Misses $(0.48) Estimate, Sales $2.58B Up From $2.57M YoY
Benzinga Newsdesk - May 4, 2023, 4:49PM
Earnings Scheduled For May 4, 2023
Benzinga Insights - May 4, 2023, 6:34AM

Wednesday, May 03, 2023

Aligos Therapeutics Earnings Preview
Benzinga Insights - May 3, 2023, 3:03PM

Tuesday, March 14, 2023

Aligos Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga Insights - Mar 14, 2023, 10:48AM

Thursday, March 09, 2023

Aligos Therapeutics Q4 EPS $(0.51) Misses $(0.47) Estimate, Sales $3.54M Beat $1.72M Estimate
Happy Mohamed - Mar 9, 2023, 4:26PM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved